| Topic: |
Sociology > Depression |
| User: |
"APG" |
| Date: |
08 Dec 2005 10:14:41 PM |
| Object: |
FDA advises of Paxil (paroxetine) birth defects risk |
FDA Advising of Risk of Birth Defects with Paxil
The Food and Drug Administration today is alerting health care
professionals and patients about early results of new studies for
Paxil (paroxetine) suggesting that the drug increases the risk for
birth defects, particularly heart defects, when women take it during
the first three months of pregnancy. Paxil is approved for the
treatment of depression and several other psychiatric disorders. FDA
is currently gathering additional data and waiting for the final
results of the recent studies in order to better understand the higher
risk for birth defects that has been seen with Paxil.
FDA is advising health care professionals to discuss the potential
risk of birth defects with patients taking Paxil who plan to become
pregnant or are in their first three months of pregnancy. Health care
professionals should consider discontinuing Paxil (and switching to
another antidepressant if indicated) in these patients. In some
patients, the benefits of continuing Paxil may be greater than the
potential risk to the fetus. FDA is advising health care professionals
not to prescribe Paxil in women who are in the first three months of
pregnancy or are planning pregnancy, unless other treatment options
are not appropriate.
FDA is advising patients that this drug should usually not be taken
during pregnancy, but for some women who have already been taking
Paxil, the benefits of continuing may be greater than the potential
risk to the fetus. Women taking Paxil who are pregnant or plan to
become pregnant should talk to their physicians about the potential
risks of taking the drug during pregnancy. Women taking Paxil should
not stop taking it without first talking with their physician.
More: http://anxpangazette.blog-city.com/
http://anxpangazette.blog-city.com/fda_advises_of_paxil_paroxetine_birth_defects_risk.htm
.
|
|
|
Related Articles |
|
|
